Literature DB >> 14763059

Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.

Alena Parikova1, Machteld M Zweers, Dirk G Struijk, Raymond T Krediet.   

Abstract

Chronic exposure to peritoneal dialysis (PD) solutions is associated with a low-grade local inflammatory state of the peritoneum. The occurrence of culture-negative peritonitis in some PD patients treated with icodextrin focused our interest on subclinical inflammation in icodextrin-treated patients without peritonitis. The aim of the present study was to compare signs of inflammation in icodextrin-treated patients with the same signs in patients using glucose/lactate-based (GL) dialysis solutions only. Overnight PD effluents from 19 patients treated with icodextrin and 19 patients treated with GL were investigated for leukocyte count (LC) and differentiation (LD), and for dialysate concentrations of cancer antigen 125 (CA125, the marker of mesothelial cell mass) and hyaluronan (marker of inflammation and tissue remodeling in the peritoneal cavity). Blood cell counts and serum dextran antibodies (DA) were also determined. Total LC in the GL group was significantly lower than that in the icodextrin group. The LD was not different between the two groups, except for the percentage of eosinophils. The blood cell count did not differ between the groups. The median value of DA was similar in both groups. The hyaluronan concentration was markedly higher in the icodextrin group. No significant difference was found for dialysate CA125. In conclusion, the higher effluent cell count, higher percentage of eosinophils, and higher effluent hyaluronan levels in icodextrin-treated patients are consistent with a greater degree of subclinical inflammation during icodextrin treatment than during GL treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14763059

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  14 in total

Review 1.  Encapsulating peritoneal sclerosis: a single-center experience and review of the literature.

Authors:  Konstantina Trigka; Periklis Dousdampanis; Maggie Chu; Saimah Khan; Mufazzal Ahmad; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2010-10-06       Impact factor: 2.370

2.  Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Authors:  Sylvie Opatrna; Daniel Lysak; Ladislav Trefil; Clare Parker; Nicholas Topley
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

3.  Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.

Authors:  Lynn Redahan; Andrew Davenport
Journal:  J Nephrol       Date:  2015-11-30       Impact factor: 3.902

4.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

Review 5.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

6.  The use of exchange-free periods alternating with daily exchanges of icodextrin in the initial treatment of peritoneal dialysis-associated peritonitis: a safety study.

Authors:  Maha Yehia; Grace Muyoma; Nicholas Topley; John F Collins
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

Review 7.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

8.  A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.

Authors:  Caatje Y le Poole; Angelique G A Welten; Piet M ter Wee; Nanne J Paauw; Amina N Djorai; Rob M Valentijn; Robert H J Beelen; Jacob van den Born; Frans J van Ittersum
Journal:  Perit Dial Int       Date:  2011-11-01       Impact factor: 1.756

Review 9.  Icodextrin and peritoneal dialysis: advantages and new applications.

Authors:  Periklis Dousdampanis; Carlos Guido Musso; Konstantina Trigka
Journal:  Int Urol Nephrol       Date:  2017-07-03       Impact factor: 2.370

10.  Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients.

Authors:  Periklis Dousdampanis; Konstantina Trigka; Joanne M Bargman
Journal:  Int J Nephrol       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.